Literature DB >> 11297600

Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects.

M S Torres1, L Ramirez, P H Simkin, L E Braverman, C H Emerson.   

Abstract

Recombinant human TSH (rhTSH), usually given as 0.9-mg doses im on 2 successive days, increases serum thyroglobulin (Tg) and radioactive iodine uptake (RAIU) in residual thyroid tissue in patients with thyroid cancer. We previously reported that a single, relatively low dose of rhTSH (0.1 mg im) is a potent stimulator of T(4), T(3), and Tg secretion in normal subjects. The present study describes the effects of higher doses of rhTSH on thyroid hormone and Tg secretion. Six normal subjects for each dose group, having no evidence of thyroid disease, received either 0.3 or 0.9 mg rhTSH by im injection. Serum TSH, T(4), T(3), and Tg concentrations were measured at 2, 4, and 8 h and 1, 2, 3, 4, and 7 days after rhTSH administration. The peak serum TSH concentrations were 82 +/- 18 and 277 +/- 89 mU/L, respectively, for the 0.3- and 0.9-mg doses of rhTSH. Serum T(4), T(3), and Tg concentrations increased significantly in subjects receiving 0.3 and 0.9 mg rhTSH, with significant increases in T(4) and T(3) being observed before significant increases in serum TG: Peak concentrations of serum T(4), T(3), and Tg, after 0.3 mg rhTSH administration, were 100 +/- 19, 131 +/- 14, and 1035 +/- 724% above individual baselines, respectively. Similarly, peak concentrations of serum T(4), T(3), and Tg, after 0.9 mg rhTSH administration, were 102 +/- 16, 134 +/- 7, and 1890 +/- 768% above individual baselines, respectively. These data, compared with previously reported data for the responses to 0.1 mg rhTSH, indicated that 0.1, 0.3, and 0.9 mg rhTSH had similar quantitative stimulatory effects on thyroid hormone and Tg secretion, except that the T(4) response was greater in groups receiving 0.3 and 0.9 mg rhTSH than in the group receiving 0.1 mg rhTSH. We also studied the effect of rhTSH on the thyroid RAIU in the group that received 0.9 mg rhTSH. The 6- and 24-h RAIU values were significantly higher after rhTSH (pre-rhTSH, 6-h value = 12.5 +/- 1.8%; 24 h value = 23 +/- 2.7%; post-rhTSH, 6 h value = 27 +/- 4.8%; 24-h value = 41 +/- 4.2%). The stimulating effects of 0.9 mg rhTSH on the 6- and 24-h RAIUs were similar. rhTSH is a potent stimulator of T(4), T(3), and Tg secretion and the RAIU in normal subjects. Single doses greater than 0.1--0.3 mg do not seem to further enhance thyroid hormone or Tg secretion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11297600     DOI: 10.1210/jcem.86.4.7405

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.

Authors:  Teng Zhao; Jun Liang; Zhenqing Guo; Jiao Li; Yansong Lin
Journal:  Endocrine       Date:  2016-01-18       Impact factor: 3.633

Review 2.  Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131I-therapy.

Authors:  Steen Joop Bonnema; Søren Fast; Laszlo Hegedüs
Journal:  Endocrine       Date:  2011-10-05       Impact factor: 3.633

Review 3.  Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Authors:  Chao Ma; Jiawei Xie; Wanxia Liu; Guoming Wang; Shuyao Zuo; Xufu Wang; Fengyu Wu
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

4.  Inability of recombinant human thyrotropin to predict the evolution from subclinical hypothyroidism to overt disease. A pilot study.

Authors:  C Zafon; B Rodríguez; J B Montoro; D Cabo; J Mesa
Journal:  J Endocrinol Invest       Date:  2011-04-26       Impact factor: 4.256

5.  Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.

Authors:  Fabian Pitoia; Erika Abelleira; Graciela Cross
Journal:  Endocrine       Date:  2016-09-21       Impact factor: 3.633

Review 6.  An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter.

Authors:  Geraldo Medeiros-Neto; Suemi Marui; Meyer Knobel
Journal:  Endocrine       Date:  2008-05-20       Impact factor: 3.633

7.  Extensions, validation, and clinical applications of a feedback control system simulator of the hypothalamo-pituitary-thyroid axis.

Authors:  Marisa Eisenberg; Mary Samuels; Joseph J DiStefano
Journal:  Thyroid       Date:  2008-10       Impact factor: 6.568

8.  Long-term efficacy of modified-release recombinant human thyrotropin augmented radioiodine therapy for benign multinodular goiter: results from a multicenter, international, randomized, placebo-controlled, dose-selection study.

Authors:  Søren Fast; Laszlo Hegedüs; Furio Pacini; Aldo Pinchera; Angela M Leung; Mario Vaisman; Christoph Reiners; Jean-Louis Wemeau; Dyde A Huysmans; William Harper; Irina Rachinsky; Hevelyn Noemberg de Souza; Maria G Castagna; Lucia Antonangeli; Lewis E Braverman; Rossana Corbo; Christian Düren; Emmanuelle Proust-Lemoine; Christopher Marriott; Albert Driedger; Peter Grupe; Torquil Watt; James Magner; Annie Purvis; Hans Graf
Journal:  Thyroid       Date:  2014-03-04       Impact factor: 6.568

Review 9.  Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

10.  Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin.

Authors:  I G S Rubio; M N C Silva; M Knobel; R Romão; R Possato; E M M S Gebrin; C Buchpiguel; G Medeiros-Neto
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.